Opinion|Videos|November 17, 2026

Why HIV Innovation Continues: New Mechanisms and the Long-Acting Pipeline

Rather than converging on a single regimen, HIV drug development is expanding choice, and the late-stage pipeline points toward weekly, twice-yearly, and potentially yearly dosing.

In "Why HIV Innovation Continues: New Mechanisms and the Long-Acting Pipeline," the panel weighs whether the growing list of HIV options is a problem or an advantage.

Dr. Burkhart rejects the idea that the field should converge on one preferred regimen. He sees expanding options as a way to individualize therapy, since patients differ in cardiovascular risk, renal disease, concomitant medications, and dosing preferences. Pill burden and pill fatigue drove the development of long-acting injectables. Resistance will always evolve, so ongoing investment helps clinicians stay ahead of the virus. Access and cost also matter, because insurance coverage varies and patients need affordable alternatives. Dr. Madison references a CROI poster showing that patients offered choice are more likely to stay adherent. Dr. Nguyen adds that patients who like their treatment, including those who prefer coming in for injections, are more motivated and achieve better outcomes.

Dr. Nguyen then reviews the late-stage pipeline. She identifies the evolution of long-acting therapy as the key trend, with treatment and prevention moving from daily dosing to every two or six months. Candidates in development include a once-weekly oral regimen combining lenacapavir with islatravir and a once-yearly lenacapavir option. She notes that bictegravir/lenacapavir was recently approved, and lenacapavir paired with broadly neutralizing antibodies has shown six-month viral suppression. The adherence challenge shifts from daily pills to keeping injection appointments within the dosing window. Clinics must also decide who administers injections, where, and how staff are trained, which could strain resources.

Dr. Madison cautions that less frequent visits should not mean missed sexual health and STI screening. Dr. Burkhart agrees that more options benefit patients. Dr. Durham observes that once-monthly prevention, once-weekly treatment, and potential once-yearly dosing reflect that different patients want different things. Some prefer oral therapy, while others strongly prefer injectables.

Funding supported by Gilead. Content independently developed by Pharmacy Times


Related to this article